Journal of Immunology Research

Review Article

Human Monoclonal Antibody-Based Therapy in the Treatment of Invasive Candidiasis

Table 1

Checkerboard assay of FLC (fluconazole), AMB, caspofungin, and Mycograb versus C. albicans fluconazole-susceptible (FLC-S) and fluconazole-resistant (FLC-R) strains.
Straints Agents MIC (µg/mL) for each agent FICI Outcome References
Alone In combination
C. albicans (FLC-S)FLC
Mycograb		1.56
128		 0.40.34Synergy Matthews et al. 2003 [19]
C. albicans (FLC-R)FLC
Mycograb		50
256		12.5
100		0.64Indifference  
C. albicans (FLC-S)AMB
Mycograb		1
128		0.03
8		0.09SynergyMatthews et al. 2003 [19]
C. albicans (FLC-R)AMB
Mycograb		0.5
256		0.125
4 		0.27Synergy 
C. albicans (FLC-S)Caspofungin
Mycograb		0.125
1024		0.0625
16		0.5SynergyHodgetts et al. 2008 [20]
C. albicans (FLC-R)Caspofungin
Mycograb		0.25
2048		0.125
0.125		0.52Indifference 
FICI: fractional inhibitory concentration index.